Victoria Socha

DocwireNews

As approval for hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors for the treatment of <a href="https://www.docwirenews.com/latest-nephrology-news/online-cme-improves-knowledge-of-emerging-treatments-for-anemia/">anemia</a> nears, focus has turned to access for patients on dialysis. According to Meghan Staudt, MBA, and colleagues at Spherix Global Insights, Exton, Pennsylvania, dialysis centers have influence over access.The researchers conducted an analysis comparing the evolution of Parsabiv&reg; (Amgen) from approval and inclusion under TDAPA (transitional drug add-on payment adjustment) to being reimbursed within the bundle as an analogue for the path the HIF-PH inhibitors may face. Results of the analysis were reported during a poster session at the NKF SCM22 in a poster titled What to Expect with the Potential Approval of HIF-PH Inhibitors in Dialysis.The analysis examined responses from more than 200 nephrologists who completed a HIPAA-compliant, online tool. Relevant data included demographic profiles, attitudinal responses, and brand share estimates quarterly from 2017 through 2021.Vadadustat, the HIF-PH in the pipeline at Akebia Therapeutics, Inc., is the first in line for FDA approval. In dialysis, vadadustat has higher familiarity among nephrologists than Parsabiv did pre-approval (29% vs 16%, respectively). The percentage of nephrologists who anticipate trialing a HIF-PH inhibitor immediately in dialysis is low (8%); however, it is higher than Parsabiv at a similar time pre-launch (3%).Barriers to using HIF-PH inhibitors are similar to those seen with Parsabiv: the top barriers for both drugs are largely related to access. Many nephrologists anticipate dialysis center protocols will dictate the use of HIF-PH inhibitors; similarly, most reported experiencing formulary issues with Parsabiv.When asked about the use of HIF-PH inhibitors in dialysis, 48% of responding nephrologists said they expected their dialysis center to primarily use erythropoiesis-stimulating agents (ESAs), 22% expect equal ESA and HIF-PH inhibitor use, and 21% expect only use of ESAs. Fifty percent of the responding nephrologists said they were concerned about safety with HIF-PH inhibitors.While nephrologists expect that most dialysis patients treated for anemia will be on ESAs, more than 80% anticipate using HIF-PH inhibitors in dialysis. In comparison, Parsabiv&rsquo;s user base rose past 80%, reaching peak share 2 years after approval under TDAPA. However, once Parsabiv was added to the Medicare bundle payment, its share eroded over time.In conclusion, the authors said, &ldquo;Vadadustat, if approved, may end up on a similar path as Parsabiv, with dialysis center protocols governing use, Although familiarity with vadadustat may aid its uptake in dialysis, safety concerns ring loud and will be a hurdle the HIF-PH inhibitor class will need to battle.&rdquo;Source: Staudt M, Malone S, Robinson J. What to expect with the potential approval of HIF-PH inhibitors in dialysis. Abstract of a poster presented at the National Kidney Foundation 2022 Spring Clinical Meetings (Abstract #179), Boston, Massachusetts, April 6-10, 2022.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Potential Approval of HIF-PH Inhibitors in Dialysis Patients

Anemia and Kidney Disease

As approval for hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors for the treatment of anemia nears, focus has turned to access for patients on dialysis. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe